OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Other EventsItem 8.01 Other Events.
On April 18, 2018, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse. The grant provides the Company with additional resources for the ongoing development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. The grant includes approximately $2.6 million to be funded for the period ending March 31, 2019, with the balance to be funded over the subsequent two years. A copy of the press release is attached hereto as Exhibit99.1 to this Current Report on Form8-Kand is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
Press Release of Opiant Pharmaceuticals, Inc., dated April 18, 2018.
OPIANT PHARMACEUTICALS, INC. ExhibitEX-99.1 2 opnt-pressreleaseapril2018.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003,…To view the full exhibit click
About OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT)
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.